Ablynx extends Nanobody collaboration with Boehringer; More action on the Russian VC front;

 @FierceBiotech: Cytos revives lead program in $40M financing deal with Amgen, venBio. News | Follow @FierceBiotech

 @JohnCFierce: NicOx (France) takes an option to buy Altacor in the U.K., with an eye to building an ophthalmology company. Release | Follow @JohnCFierce

 @RyanMFierce: Hepatera, a Russian biotech, has grabbed a mystery amount of funding for a hepatitis program. Release | Follow @RyanMFierce

@FierceMedDev: Stryker Stent May Not Be Worth the Stroke Risks, FDA Says via @BloombergNews. Story | Follow @FierceMedDev

> The Belgian biotech Ablynx ($ABLX) has inked a two-year extension to its collaboration with German drugmaker Boehringer Ingelheim to advance up to 10 Nanobody drugs, providing Ablynx with an additional 6.6 million euros. Release

> Recently formed Russian biotech Hepatera and its German partner MYR have raised an undisclosed amount of funding from Moscow-based Maxwell Biotech Venture Fund and venture firm High-Tech Gründerfonds of Germany. Release

> UCB Pharma has committed £3.6 million ($5.7 million) over the next three years in its collaboration with Oxford University to research drugs in immunology and neurology. Report

Pharma News

 @FiercePharma: Pfizer to pay $3.3M to settle Zyvox probe. Story | Follow @FiercePharma

> Teva to jump to NYSE. News

> Targacept management acknowledges layoffs are possible. More

> Pharma sales execs: Current model is broken; changes are coming. Article

> Sandoz: We won't hike prices in Canada during shortage. Story

> FDA panel backs GSK's Votrient for soft-tissue sarcoma. News

Biomarkers News

> There may be more to mesothelioma than mesothelin. Item

> RNA could predict cancer recurrence risk. Article

> Triple-negative breast cancer biomarker points to new cancer model. More

> Study: Alzheimer's not prevented by antioxidants. Story

Drug Delivery News

> Bend Research, in nod to Pfizer, eyes biotherapeutics drug delivery. Story

> Echo Therapeutics reports $16.7M loss after Prelude delay. More

> U.K. CF gene therapy trials to test inhaled and viral delivery options. Article

Medical Device News

> Olympus confronts scandal with 3 new surgical devices. News

> U.S. Supreme Court KOs Prometheus Labs' test patent suit. More

> Genoptix test to guide melanoma treatment decisions. Story

> J&J lawsuit bombshell: Company marketed vaginal mesh minus FDA nod. Article

And Finally… In favor of biologics, a gap between the numbers of patents filed for biotech drugs versus those for small molecules is growing. Item

Suggested Articles

Biogen will develop a gene therapy with the goal of preserving and possibly restoring vision in patients with PRPF31-mutated retinitis pigmentosa.

A month after moving its COVID-19 antibody cocktail into human trials, Regeneron is testing the drug's ability to ward off COVID-19 infection.

Short reports are nothing new, but the aggressive “I’m coming after you” PR from Applied Therapeutics certainly is.